The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …

Opinion statement The management of metastatic castrate-resistant prostate cancer
(mCRPC) has evolved in the past decade due to substantial advances in understanding the …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

Immunotherapy is a powerful technique where immune cells are modified to improve
cytotoxicity against cancerous cells to treat cancers that do not respond to surgery …

PARP inhibitors have gained attention in the treatment of metastatic castration-resistant
prostate cancer, but approximately half of patients have to abort treatment due to severe …

Purpose Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that
imposes a major burden on patients and healthcare systems. Three structured literature …

ABSTRACT Introduction Prostate cancer (PCa) is the second most common cancer
diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment …

The functional heterogeneity and ecological niche of prostate cancer stem cells (PCSCs),
which are major drivers of prostate cancer development and treatment resistance, have …

Background and purpose There is growing concern about the adverse metabolic and
cardiovascular effects of abiraterone acetate (AA) and enzalutamide (ENZ), two standard …

Background and objective Next-line systemic treatment (NEST) is the standard of care for
patients presenting with progressive metastatic castration-resistant prostate cancer …